Development and validation of a stability indicating uplc method for determination of erlotinib in pharmaceutical formulations

Der Pharma Chemica

Volumn 4, Issue 6, 2012, Pages 2288-2297

  Naveen Kumar Reddy, G ^a   Rajendra Prasad, V V S ^b   Maharana, Prashant Kumar ^b  

^a CMJ University   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Assay method; Erlotinib; Stability indicating method; UPLC

Indexed keywords

ERLOTINIB;

ACCURACY; ANALYTIC METHOD; ARTICLE; DRUG DETERMINATION; DRUG STABILITY; DRUG STRUCTURE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; PROCESS DEVELOPMENT; SEPARATION TECHNIQUE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION STUDY;

EID: 84872794051     PISSN: None     EISSN: 0975413X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Michael E. Swartz Waters Corporation, Milford, Massachusetts, USA UPLCTM: An Introduction and Review.
2. FDA Guidance for Industry. Analytical Procedures and Methods Validation (draft guidance), August 2000.
3. http://www.centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=867
4. www.drugbank.ca/drugs/DB00218
5. www.chemblink.com
6. Perez-Soler R, Chachoua A, Hammond LA, et al.. Journal of Clinical Oncology 2004 Aug 15; 22(16):3238-47.
7. Higgins B, Kolinsky K, Smith M, et al.. Anticancer Drugs 2004 Jun;15(5):503-12.
8. Perez-Soler R. Clinical Cancer Research 2004 Jun 15; 10(12 Pt 2):4238s-4240.
9. Gadekal Siva Sai Geetha, J. Raveendra Reddy, P. Ramalingam, P. Malleshwari, Am. J. Pharm Tech Res. 2012; 2(5)
10. Validation of Analytical Procedures: Text and Methodology Q2 (R1).